GFM
ENTA icon

GF Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

GF Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Sell
617
-23
-4% -$309 ﹤0.01% 545
2026
Q1 		$8.08K Buy
640
+75
+13% +$1K ﹤0.01% 579
2025
Q4 		$8.91K Buy
565
+117
+26% +$1.49K ﹤0.01% 584
2025
Q3 		$5.36K Sell
448
-77
-15% -$615 ﹤0.01% 607
2025
Q2 		$3.97K Hold
525
– – ﹤0.01% 637
2025
Q1 		$2.9K Buy
525
+80
+18% +$494 ﹤0.01% 642
2024
Q4 		$2.56K Buy
+445
New +$4.27K ﹤0.01% 632

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GF Fund Management's ENTA Position: Q2 2026 in Review

GF Fund Management reduced its Enanta Pharmaceuticals (ENTA) stake by 3.6% in Q2 2026, selling an estimated $309 and leaving 617 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #545.

GF Fund Management first reported a position in ENTA in Q4 2024 and has held it in 7 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • GF Fund Management held 617 shares of Enanta Pharmaceuticals worth $9K as of Q2 2026.
  • GF Fund Management sold 23 Enanta Pharmaceuticals shares in Q2 2026, an estimated $309.
  • Enanta Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #545 holding.
  • GF Fund Management first reported a position in Enanta Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.